ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconFacebook IconIcon FacebookGoogle Plus IconLayer 1InstagramCreated with Sketch.Linkedin IconIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerIcon Opinion QuotePositive ArrowIcon PrintRSS IconIcon SearchSite TitleTitle ChevronTwitter IconIcon TwitterYoutube Icon
Health Technology

Lupin Ltd.

  • 818.00 INR
  • -1.10
  • -0.13%
  • India
    Apr 24, 2018
  • Ticker
  • Prev. close
  • Market cap (INR)
  • Market cap (USD)
  • Shares

Company Background

Lupin is a major generic drugmaker that conducts business in more than 100 countries. Among India's five biggest pharmaceuticals, it has about 10 production bases in India and exports generic drugs to other countries.

It was founded in 1968 by Desh Bandhu Gupta, a researcher at a science university. Since the early 2000s, it has been actively buying companies in South Africa, Mexico, even Japan.

It got a head start on its Indian competitors by building a supply network in Japan. It did so in 2007 by acquiring Kyowa Pharmaceutical Industry, an Osaka-based medium-size generic drugmaker. In 2014, it set up a venture with Yoshindo, a generic drug company based in Japan's Toyama Prefecture, to jointly develop generic biomedicines.

Zyma Laboratories, an affiliate company run by Desh Bandhu Gupta and other executives, is Lupin's top shareholder; the founding family still owns some shares in Lupin.

Business Summary

Lupin Ltd. operates as a pharmaceuticals company. It manufactures and distributes pharmaceutical ingredients and formulations. The company offers products in growth therapy segments, such as cardiology, central nervous system, anti-diabetic, anti-TB, anti-asthma, gynaecology, anti-infective, gastro-intestinal and others. Lupin was founded by Desh Bandhu Gupta in 1968 and is headquartered in Mumbai, India.

Financial Highlights

Mar 2017 INRUSD
Gross Profit83,802.20M1,249.71M
Operating income37,023.70M552.12M
Income before tax35,348.90M527.14M
Net income25,574.60M381.38M
Diluted EPS56.460.84
Dividends Per Share7.500.11
Total Assets266,072.80M4,097.52M
Total liabilities130,751.90M2,013.58M
Total equity134,966.50M2,078.48M
Operating cash flow40,105.20M598.07M
Currency in INRCurrency in USD

Historical Data

 Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017
Revenue 94,616.30M 110,859.10M 125,988.70M 137,818.50M 170,305.30M
Gross Profit 33,745.60M 44,273M 59,588.70M 67,159.10M 83,802.20M
Operating income 18,395.80M 26,508.20M 31,579.50M 32,615.50M 37,023.70M
Income before tax 19,246M 28,316.50M 34,148.30M 33,239.40M 35,348.90M
Net income 13,141.60M 18,363.70M 24,032.40M 22,607.40M 25,574.60M
EBITDA 21,717.70M 29,117.90M 35,926.50M 37,486.80M 46,146M
Diluted EPS 29.26 40.79 53.20 49.93 56.46
Dividends Per Share 4 6 7.50 7.50 7.50
Total Assets 89,679.20M 102,753.50M 132,271.80M 226,248.60M 266,072.80M
Total liabilities 37,042.90M 32,768.40M 43,290.20M 114,294.10M 130,751.90M
Total equity 52,032.60M 69,306.50M 88,731.40M 111,624.50M 134,966.50M
Operating cash flow 12,204M 19,906.70M 27,947M -4,269.70M 40,105.20M
 Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017
Revenue 1,738.45M 1,834.37M 2,060.54M 2,105.03M 2,539.70M
Gross Profit 620.03M 732.58M 974.57M 1,025.78M 1,249.71M
Operating income 337.99M 438.62M 516.48M 498.16M 552.12M
Income before tax 353.62M 468.55M 558.49M 507.69M 527.14M
Net income 241.46M 303.86M 393.04M 345.30M 381.38M
EBITDA 399.03M 481.81M 587.57M 572.57M 688.16M
Diluted EPS 0.53 0.67 0.87 0.76 0.84
Dividends Per Share 0.07 0.09 0.12 0.11 0.11
Total Assets 1,650.03M 1,720.51M 2,113.60M 3,416.49M 4,097.52M
Total liabilities 681.56M 548.67M 691.74M 1,725.91M 2,013.58M
Total equity 957.36M 1,160.47M 1,417.85M 1,685.59M 2,078.48M
Operating cash flow 224.23M 329.39M 457.07M -65.21M 598.07M

Valuation Measures

Mar 2017
Operating margin21.73%
Profit margin15.01%

Key executives

  • Managing Director & Executive Director: Nilesh Deshbandhu Gupta
  • Chief Executive Officer & Executive Director: Vinita D. Gupta
  • Chief Financial Officer & Executive Director: Ramesh Swaminathan
  • President-Technical Operations: Alok Ghosh
  • Secretary & Compliance Officer: Rajvardhan V. Satam


  • Lupin Investments Pvt Ltd. (45.4%)
  • Life Insurance Corp. of India (2.6%)
  • First State Investment Management (UK) Ltd. (2.4%)
  • Genesis Investment Management LLP (2.3%)
  • The Vanguard Group, Inc. (1.6%)
  • ICICI Prudential Asset Management Co. Ltd. (1.6%)
  • BlackRock Fund Advisors (1.5%)
  • Norges Bank Investment Management (1.2%)
  • Fidelity Management & Research Co. (1.0%)

Contact Details

Related Companies

  • Lupin Atlantis Holdings SA
  • Lupin Farmaceutica Do Brasil Ltda.
  • Lupin Pharmaceuticals Ltd/Brazil/
  • Lupin Employees Benefit Trust
  • Nanomi BV
  • Lupin Healthcare Ltd.
  • GAVIS Pharmaceuticals LLC
  • Lupin Chemical (Thailand) Ltd.
  • Lupin Holdings B.V., Netherlands
  • Polynova Industries Ltd.
  • Lupin Laboratories Ltd.
  • Laboratorios Grin SA de CV
  • Lupin Pharmaceuticals, Inc.
  • Multicare Pharmaceuticals Philippines, Inc.
  • Pharma Dynamics Pty Ltd.
  • Hormosan Pharma GmbH
  • Kyowa Pharmaceutical Industry Co., Ltd.
  • Rubamin Laboratories Ltd.
  • Lupin Chemicals Ltd.
  • Temmler Pharma GmbH & Co. KG
  • Lupin Herbal Pvt. Ltd.


  • Dr. Reddy's Laboratories Ltd.
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Limited
  • Cipla Limited
  • Endo International Plc
  • STADA Arzneimittel AG
  • Perrigo Co. Plc
  • Sun Pharmaceutical Industries Limited
  • Aspen Pharmacare Holdings Limited
  • Aurobindo Pharma Ltd
  • GlaxoSmithKline Pharmaceuticals Limited
  • Biocon Limited
  • Unichem Laboratories Limited
  • Impax Laboratories, Inc.
  • Gemphire Therapeutics Inc.
  • Hikma Pharmaceuticals Plc
  • Agile Therapeutics, Inc.
  • Midatech Pharma Plc
  • Momenta Pharmaceuticals, Inc.
Last Updated on 24 Apr, 2018

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

Get unlimited access
NAR site on phone, device, tablet

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

3 months for $9

Get unlimited access
NAR site on phone, device, tablet

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media